Drugs / CMVpp65-A*0201 peptide vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00712634 | Nov 1997 → Apr 2009 | precancerous condition | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02396134 | May 2015 → Mar 2018 | Hodgkins lymphoma, acute myeloid leukemia, adult acute lymphoblastic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +4 | City of Hope Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMVpp65-A*0201 peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02396134 ↗ |
| Modality | Vaccine | “CMVpp65-A*0201 peptide vaccine” NCT00712634 ↗ |
| Route | Subcutaneous | “Participants receive the vaccine or a placebo subcutaneously (SC)” NCT00712634 ↗ |